MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
4.030
-0.080 (-1.95%)
Sep 10, 2026, 11:03 AM EDT - Market open
MacroGenics Employees
MacroGenics had 293 employees as of December 31, 2025. The number of employees decreased by 48 or -14.08% compared to the previous year.
Employees
293
Change (1Y)
-48
Growth (1Y)
-14.08%
Revenue / Employee
$597,754
Profits / Employee
-$49,802
Market Cap
256.71M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 293 | -48 | -14.08% |
| Dec 31, 2024 | 341 | 2 | 0.59% |
| Dec 31, 2023 | 339 | -18 | -5.04% |
| Dec 31, 2022 | 357 | -70 | -16.39% |
| Dec 31, 2021 | 427 | 57 | 15.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Entrada Therapeutics | 152 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Alector | 103 |
| Lineage Cell Therapeutics | 77 |
| Cartesian Therapeutics | 75 |
| Camp4 Therapeutics | 48 |
MGNX News
- 19 hours ago - MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 24 days ago - MacroGenics price target raised to $11 from $9 at B. Riley - TheFly
- 25 days ago - MacroGenics reports Q2 EPS 31c, consensus 26c - TheFly
- 27 days ago - MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - GlobeNewsWire
- 27 days ago - MacroGenics Earnings release: Q2 2026 - Filings
- 27 days ago - MacroGenics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - MacroGenics Slides: Corporate presentation - Filings
- 4 weeks ago - MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program - GlobeNewsWire